newsfilter
← Latest News
GlobeNewswire·

Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2023

Initial data from the Phase 1 clinical trial of IMVT-1402 on track for September 2023 (single-ascending dose) and October/November 2023 (multiple-ascending dose) Phase 2 proof-of-concept data for batoclimab in Graves'